Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5340-5350

  Yu, Hyun Kyung ^a,b   Lee, Ho Jeong ^a,e   Choi, Ha Na ^a   Ahn, Jin Hyung ^a   Choi, Ji Young ^c   Song, Haeng Seok ^c   Lee, Ki Heon ^c   Yoon, Yeup ^a   Yi, Lee S H ^b   Kim, Jang Seong ^d   Kim, Sun Jin ^e   Kim, Tae Jin ^c  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; ENDOGLIN; HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CELLULAR DISTRIBUTION; CIRCULATING ENDOTHELIUM CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD45; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE;

EID: 84886423395     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3685     Document Type: Article

References (54)

1. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:998-1003.
2. Jung YD, Ahmad SA, Akagi Y, Takahashi Y, Liu W, Reinmuth N, et al. Role of the tumor microenvironment in mediating response to antiangiogenic therapy. Cancer Metastasis Rev 2000;19:147-57.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
5. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73.
6. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5:378-91.
7. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45.
8. Li N, Zheng D, Wei X, Jin Z, Zhang C, Li K. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol 2012;138:1131-44.
9. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
10. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4.
11. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
12. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31.
13. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer 2011; 105:112-7.
14. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010;21:2382-9.
15. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9.
16. Schmeisser A, Strasser RH. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. J Hematother Stem Cell Res 2002;11:69-79.
17. Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW. Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 2007;72: 86-93.
18. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 2009;69:108-24.
19. Goon PK, Watson T, Shantsila E, Boos CJ, Lip GY. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost 2007;5:870-2.
20. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 2006;373:17-26.
21. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006;24:1449-53.
22. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005;105:679-81.
23. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003;108: 2511-6.
24. Kim SJ, Kim JS, Papadopoulos J, Wook Kim S, Maya M, Zhang F, et al. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 2009;174:1972-80.
25. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007;2:805-10.
26. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50.
27. Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, et al. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 2011;13:980-90.
28. Wierzbowska A, Robak T, Krawczynska A, Pluta A, Wrzesien-Kus A, Cebula B, et al. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 2008;87:97-106.
29. Robinson JP. Current protocols in cytometry. New York: Wiley; 1998
30. Tung JW, Heydari K, Tirouvanziam R, Sahaf B, Parks DR, Herzenberg LA. Modern flow cytometry: a practical approach. Clin Lab Med 2007;27:453-68.
31. Cui YX, Johnson T, Baumbach A, Reeves BC, Rogers CA, Angelini GD, et al. Stepwise optimization of the procedure for assessment of circulating progenitor cells in patients with myocardial infarction. PLoS ONE 2012;7:e30389.
32. McLean K, Buckanovich RJ. Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl Res 2008; 151:59-67.
33. Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Fae I, Waclavicek M, et al. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J Immunol 1997;158:2107-15.
34. George F, Brisson C, Poncelet P, Laurent JC, Massot O, Arnoux D, et al. Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992;67:147-53.
35. Strijbos MH, Verhoef C, Gratama JW, Sleijfer S. On the origin of (CD105+) circulating endothelial cells. Thromb Haemost 2009;102: 347-51.
36. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995;92:2428-32.
37. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
38. Rohde E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, Lanzer G, et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006;24:357-67.
39. Schmeisser A, Graffy C, Daniel WG, Strasser RH. Phenotypic overlap between monocytes and vascular endothelial cells. Adv Exp Med Biol 2003;522:59-74.
40. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164-9.
41. Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, Verhoef C, et al. A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 2012;10: 931-9.
42. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009;15:267-73.
43. Li Q, Yu Y, Bischoff J, Mulliken JB, Olsen BR. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J Pathol 2003;201:296-302.
44. Li W, Yang D, Wang S, Guo X, Lang R, Fan Y, et al. Increased expression of CD146 and microvessel density (MVD) in invasive micropapillary carcinoma of the breast: comparative study with invasive ductal carcinoma-not otherwise specified. Pathol Res Pract 2011;207:739-46.
45. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941-67.
46. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers forANCA-associated smallvessel vasculitis. Lancet 2003;361:206-10.
47. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010;86:12-9.
48. Newman PJ. The biology of PECAM-1. J Clin Invest 1997;100:S25-9.
49. Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001;49:671-80.
50. Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009;114:723-32.
51. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64.
52. Seta N, Kuwana M. Human circulating monocytes as multipotential progenitors. Keio J Med 2007;56:41-7.
53. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
54. Li B, Pozzi A, Young PP. TNFalpha accelerates monocyte to endothelial transdifferentiation in tumors by the induction of integrin alpha5 expression and adhesion to fibronectin. Mol Cancer Res 2011;9: 702-11.